Sort   by:  
 Page size 
UnknownAssociation Between Urinary Biomarkers and CKD in Extremely Low Gestational Age Neonates.

Rationale & objective

Children born before 28 weeks' gestation are at increased risk of chronic kidney disease (CKD). Urine biomarkers may shed light on mechanistic pathways and improve the ability to forecast CKD. We evaluated whether urinary biomarkers in neonates of low gestational age (G...
S-EPMC10960703 | biostudies-literature
UnknownTrial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.

Background

Neonatal hypoxic-ischemic encephalopathy is an important cause of death as well as long-term disability in survivors. Erythropoietin has been hypothesized to have neuroprotective effects in infants with hypoxic-ischemic encephalopathy, but its effects on neurodevelopmental outcome...
S-EPMC10542745 | biostudies-literature
UnknownA Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants.

Background

High-dose erythropoietin has been shown to have a neuroprotective effect in preclinical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy; however, the benefits and safety of this therapy in extremely preterm infants have not been established.
S-EPMC7060076 | biostudies-literature
UnknownTransfusions and neurodevelopmental outcomes in extremely low gestation neonates enrolled in the PENUT Trial: a randomized clinical trial.

Background

Outcomes of extremely low gestational age neonates (ELGANs) may be adversely impacted by packed red blood cell (pRBC) transfusions. We investigated the impact of transfusions on neurodevelopmental outcome in the Preterm Erythropoietin (Epo) Neuroprotection (PENUT) Trial population...
S-EPMC7797706 | biostudies-literature
UnknownDeaths in a Modern Cohort of Extremely Preterm Infants From the Preterm Erythropoietin Neuroprotection Trial.

Importance

Understanding why and how extremely preterm infants die is important for practitioners caring for these infants.

Objective

To examine risk factors, causes, timing, and circumstances of death in a modern cohort of extremely preterm infants.

Design, setting, and participan...

S-EPMC8822378 | biostudies-literature
UnknownAssociation between Term Equivalent Brain Magnetic Resonance Imaging and 2-Year Outcomes in Extremely Preterm Infants: A Report from the Preterm Erythropoietin Neuroprotection Trial Cohort.

Objectives

To compare the term equivalent brain magnetic resonance imaging (MRI) findings between erythropoietin (Epo) treated and placebo control groups in infants 240/7-276/7 weeks of gestational age and to assess the associations between MRI findings and neurodevelop...
S-EPMC9052881 | biostudies-literature
UnknownPrevalence and Risk Factors for Kidney Disease and Elevated BP in 2-Year-Old Children Born Extremely Premature.

Background and objectives

Extremely low gestational age neonates born <28 weeks gestation are at risk for chronic disease. We sought to describe the prevalence of kidney outcomes by gestational age and determine risk factors for their development.

Design, setting, participants, & measurem...

S-EPMC9435989 | biostudies-literature
UnknownIron supplementation and the risk of bronchopulmonary dysplasia in extremely low gestational age newborns.

Background

The aim of this study was to determine the relationship between iron exposure and the development of bronchopulmonary dysplasia (BPD).

Methods

A secondary analysis of the PENUT Trial dataset was conducted. The primary outcome was BPD at 36 weeks gestational age and primary ...
S-EPMC9763546 | biostudies-literature
UnknownInterleukin-2 therapy in patients with HIV infection.

Background

Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increases is not known.

Methods

We conducted two trials: the Subcutaneous Recombina...
S-EPMC2869083 | biostudies-literature
UnknownTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.

Background

Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.

Methods

A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study...
S-EPMC7576974 | biostudies-literature
Sort   by:  
 Page size